Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.
Conditions: Pancreatic Cancer Non-resectable, Tumor Pancreas, Pain Cancer
Eligibility Criteria
Inclusion Criteria
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
Exclusion Criteria
- Allergy to bupivacaine, or alcohol
- Potentially operable after neoadjuvant therapy
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Previous percutaneous or EUS-guided CGN/ CPN
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.